dc.contributor.author |
Watz, Henrik |
dc.contributor.author |
Troosters, Thierry |
dc.contributor.author |
Beeh, Kai M. |
dc.contributor.author |
García Aymerich, Judith |
dc.contributor.author |
Paggiaro, Pierluigi |
dc.contributor.author |
Molins, Eduard |
dc.contributor.author |
Notari, Massimo |
dc.contributor.author |
Zapata, Antonio |
dc.contributor.author |
Jarreta, Diana |
dc.contributor.author |
Garcia Gil, Esther |
dc.date |
2017-10-05T11:34:41Z |
dc.date |
2017-10-05T11:34:41Z |
dc.date |
2017-08-24 |
dc.date |
2017-10-04T18:00:04Z |
dc.identifier.citation |
1176-9106 |
dc.identifier.uri |
http://hdl.handle.net/2445/116223 |
dc.format |
14 p. |
dc.format |
application/pdf |
dc.language.iso |
eng |
dc.publisher |
Dove Press |
dc.relation |
Reproducció del document publicat a:
http://dx.doi.org/10.2147/COPD.S143488 |
dc.relation |
International Journal of Chronic Obstructive Pulmonary Disease,
2017, vol. 12, num. , p. 2545-2558 |
dc.relation |
http://dx.doi.org/10.2147/COPD.S143488 |
dc.rights |
cc by-nc (c) Watz et al., 2017 |
dc.rights |
info:eu-repo/semantics/openAccess |
dc.rights |
http://creativecommons.org/licenses/by-nc/3.0/es |
dc.subject |
Malalties pulmonars obstructives cròniques |
dc.subject |
Condició física |
dc.subject |
Chronic obstructive pulmonary diseases |
dc.subject |
Physical fitness |
dc.title |
ACTIVATE: the effect of aclidinium/formoterol on hyperinflation,
exercise capacity, and physical activity in patients with COPD |
dc.type |
info:eu-repo/semantics/article |
dc.type |
info:eu-repo/semantics/publishedVersion |
dc.description.abstract |
The Phase IV, 8-week, randomized, double-blind,
placebo-controlled ACTIVATE study (NCT02424344) evaluated the
effect of aclidinium/formoterol (AB/FF) 400/12 mug twice daily
on lung hyperinflation, exercise capacity, and physical activity
in patients with moderate-to-severe COPD. Patients received
AB/FF (n=134) or placebo (n=133) (1:1) via the
Genuair/Pressair(R) dry powder inhaler for 8 weeks. From Weeks 5
to 8, all patients participated in behavioral intervention (BI;
daily messages providing step goals). The primary end point was
trough functional residual capacity (FRC) at Week 4. Exercise
endurance time and physical activity were assessed at Week 4
(pharmacotherapy only) and at Week 8 (8 weeks of pharmacotherapy
plus 4 weeks of BI). Other end points included post-dose FRC,
residual volume, and inspiratory capacity (IC) at rest and
during exercise. After 4 weeks, trough FRC improved with AB/FF
versus placebo but did not reach significance (125 mL;
P=0.0690). However, post-dose FRC, residual volume, and IC at
rest improved significantly with AB/FF at Week 4 versus placebo
(all P<0.0001). AB/FF significantly improved exercise
endurance time and IC at isotime versus placebo at Week 4
(P<0.01 and P<0.0001, respectively) and Week 8 (P<0.05
and P<0.0001, respectively). AB/FF achieved higher step
counts (P<0.01) with fewer inactive patients (P<0.0001) at
Week 4 versus placebo. Following BI, AB/FF maintained
improvements in physical activity at Week 8 and nonsignificant
improvements were observed with placebo. AB/FF 400/12 mug
demonstrated improvements in lung hyperinflation, exercise
capacity, and physical activity versus placebo that were
maintained following the addition of BI. A 4-week period of BI
might be too short to augment the improvements of physical
activity observed with AB/FF. |